New combo aims to boost CAR-T success in tough lymphoma
NCT ID NCT07489989
First seen Mar 25, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study tests whether adding two drugs—chidamide and a PD-1 inhibitor—after CAR-T cell therapy can help people with relapsed or hard-to-treat B-cell lymphoma stay cancer-free longer. About 30 adults with aggressive lymphoma that has come back or not responded to treatment will receive this combination as maintenance therapy. The goal is to reduce relapse rates and improve survival by overcoming resistance and boosting the immune system's attack on cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.